The 340B Drug Pricing Program started in 1992. Congress created it to help certain healthcare providers buy outpatient drugs at lower prices. These providers are called covered entities. They get discounts that can be from 25% to 50%. This helps them use federal funds more efficiently. It also helps low-income people, uninsured or underinsured patients, and communities that need more medical care across the United States.
The Health Resources and Services Administration (HRSA) and the Office of Pharmacy Affairs (OPA) manage the program. Covered entities include federally qualified health centers (FQHCs), Critical Access Hospitals (CAHs), Disproportionate Share Hospitals (DSHs), specialty clinics, and other providers that serve many underserved people. More than 12,000 entities and about 38,000 sites take part in the program. Contract pharmacies also help distribute the discounted drugs.
The Affordable Care Act made more organizations eligible for the program. It also allowed more use of contract pharmacies. These changes helped the program grow quickly.
In 2021, purchases with discounts under the program reached $44 billion, which was 16% more than the year before. By 2018, the program made up nearly 7% of the total U.S. drug market. That year, $94 billion worth of discounted drugs were sold through 340B. This shows the program’s large role in outpatient drug supply in the country.
The main goal of the 340B program is to help safety-net providers use federal money to serve more patients and improve care. Hospitals like CAHs and DSHs, and community health centers (CHCs), pay less for outpatient drugs because of the program. This lets them spend savings on other patient care needs.
Money saved from 340B often supports services like behavioral health programs, housing help, food pantries, co-pay help, translation services, and building repairs. Ryan Klosky, a Regional Director at McKesson Medical-Surgical, says that 340B savings help reduce barriers to health care and support better primary and behavioral health services in these safety-net places.
The program is very important in rural and underserved areas. It helps providers afford expensive drugs. It also helps patients get medicines they need to manage chronic diseases, infections, and other health problems. This is especially important where local pharmacies have closed. Between 2018 and 2023, 5.9% of rural retail pharmacies shut down, creating “pharmacy deserts.” Medicare patients in rural areas visit community pharmacists more often than primary care doctors. Pharmacists do more than give out medicine. The program helps these providers keep drug costs low despite staff shortages and financial stress.
Even though the program helps many, it is complex and has some problems. There are issues with compliance, oversight, financial motives, and transparency.
One big problem found by HRSA audits is wrong or missing record-keeping. In 2023, over half the audit problems were about incorrect records in the 340B Office of Pharmacy Affairs Information System (OPAIS). This can cause compliance risks like duplicate discounts and drug diversion. A duplicate discount means a drug bought at a 340B price is also billed to Medicaid, which is not allowed and may have to be paid back. In FY23, 25% of audits found this problem.
Another issue is incomplete or incorrect Medicaid Exclusion Files (MEF), seen in 32% of FY23 audits. These files prevent duplicate discounts and make sure billing follows state Medicaid laws. Hospitals and providers must keep good records about patient eligibility, prescriptions, and pharmacy contracts to avoid problems that can risk their program participation.
Some research shows hospitals in the 340B program may not always give more charity care as expected. In 2014, about 40% of 340B hospitals gave less charity care than the national average. The Government Accountability Office (GAO) and others found that the program has changed healthcare delivery. Hospitals bought more community specialty practices and drug spending, especially for cancer treatment, increased. Medicare payments for cancer care went up 8.4% in new 340B areas between 2012 and 2017. This was partly because of more chemotherapy visits at hospital outpatient places.
The program’s fast growth and complex pharmacy contracts make oversight hard. Drug makers want limits on contract pharmacy use and ask for detailed drug claims to avoid unauthorized discounts. The Biden administration says these limits are illegal and wants rules enforced fairly.
There is also worry about how covered entities use 340B money. Federal rules do not require reporting on how savings are spent. Some hospitals make big profits. In 2018, 340B hospitals made about $13 billion in gross profits from retail drug sales. Profit margins for brand-name 340B drugs ranged from 15% to 20%. Some say these profits do not always help patients directly.
Hospital leaders, practice owners, and IT managers must keep up with 340B rules and work efficiently. The program has detailed rules on patient eligibility, drug buying, Medicaid billing, and pharmacy contracts. These require accurate data tracking and fast updates.
Artificial intelligence (AI) and automation can help a lot. AI tools can check many claims and confirm patient status—whether outpatient or inpatient. This helps stop drug diversion and duplicate discount problems. These tools can also update Medicaid exclusion files and match pharmacy contracts with OPAIS data, making records more accurate.
Simbo AI, a company that offers AI phone automation and answering services, provides technology to improve communication in healthcare. Automating front-office tasks cuts down on work and lets staff focus more on compliance and patient care. For 340B providers, AI can help with scheduling, patient checks, and pharmacy coordination, reducing errors that cause wrong drug billing.
Automated alerts can warn pharmacy managers and compliance officers when drug prices or formularies change in the HRSA Office of Pharmacy Affairs. This helps organizations stay on top of quarterly price updates and budget control.
AI also helps track state Medicaid laws and billing rules. By regularly checking claims, AI finds unusual cases or risks in clinics or pharmacies. This helps keep contracts in line and avoids duplicate discounts.
Using AI for data-driven compliance gives administrators a clear way to manage 340B requirements and improve workflow. It also lessens the load of routine self-audits and reports, lowering the chance of costly audit problems.
Medical practice administrators managing 340B need to watch compliance and audit readiness carefully. In FY23, 83% of HRSA audits were in hospitals like Critical Access Hospitals and Disproportionate Share Hospitals. Administrators must keep updates on patient eligibility, pharmacy contracts, and Medicaid exclusion files well documented and current in electronic records.
IT managers must set up systems that link clinical, pharmacy, and billing data correctly. AI automation helps manage these data flows and keeps patient records and drug claims consistent. Automated workflows reduce human errors from manual tasks.
In rural and underserved areas with fewer resources, AI and automation improve access to 340B benefits by better managing drug supplies and costs. Telepharmacy, supported by automated communication, expands pharmacy services where pharmacies have closed or workers are scarce.
Good teamwork between hospital leaders, pharmacy managers, IT departments, and compliance staff makes sure that the 340B program provides affordable medicine to those who need it without risking audit problems or financial penalties.
The 340B Drug Pricing Program is an important federal program that helps make outpatient medicines more affordable for vulnerable people and safety-net providers in the U.S. It gives financial help that lets healthcare providers offer more services to underserved patients. But the program has complicated rules, changing regulations, oversight issues, and questions about how the money is used.
Healthcare groups managing 340B programs, especially administrators, owners, and IT staff, face the challenge of saving money while following rules. AI automation and workflow tools help providers handle patient data, drug claims, and pharmacy contracts better while reducing audit risks. Companies like Simbo AI offer AI-based front-office solutions to ease these challenges in healthcare.
In a healthcare system that changes fast because of money, rules, and technology, careful management with advanced tech and good administration is needed. This helps keep providers financially stable and makes sure patients can still get affordable medicines and quality care.
The 340B Drug Pricing Program allows covered entities, such as certain hospitals and clinics, to purchase outpatient drugs at reduced prices, aiding in financial sustainability and access to medication for vulnerable populations.
The Health Resources and Services Administration (HRSA) and the Office of Pharmacy Affairs (OPA) are responsible for administering the 340B Program.
Since FY21, HRSA has increased scrutiny on Medicaid fee-for-service (FFS) billing items, focusing on compliance concerning duplicate discounts.
In FY23, the most common audit findings include inaccurate 340B OPAIS records (51%) and incomplete Medicaid Exclusion Files (32%).
In FY23, 38% of HRSA audits were completed with no adverse findings.
Entities should ensure registered pharmacies match locations in service agreements, remove closed pharmacies, and maintain accurate documentation on physical addresses.
A duplicate discount finding occurs when 340B purchased drugs are also billed for Medicaid FFS, leading to the requirement of repayment to the manufacturer.
To comply, develop a process to regularly review claims data across all sites where Medicaid is a payer, ensuring adherence to state-specific billing requirements.
The leading cause of diversion findings is administering 340B drugs to inpatients, which is not compliant with 340B eligibility.
Organizations should implement robust compliance plans, regularly review Medicaid claims, and maintain accurate electronic medical records to substantiate care related to eligible prescriptions.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
